Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin

Not Applicable

Completed

• Conditions: Laryngopharyngeal Reflux
• Interventions: Device: UESAD

• Registration Number: NCT02552966
• Lead Sponsor: Northwestern University

Brief Summary

It is postulated that the incompetence of the upper esophageal sphincter (UES) to restrict passage of esophageal refluxate is fundamental to the development of LPR. The UES Assist Device (UESAD) is a novel device that applies relatively modest external cricoid pressure, which results in a 20 to 30 mmHg intraluminal UES pressure increase. Pepsin, a proteolytic enzyme produced in the stomach, has been detected in the laryngeal epithelium of patients with reflux associated laryngeal symptoms and implicated in the pathogenesis of laryngopharyngeal reflux. This study will assess the effectiveness of a UESAD worn for 2 weeks on LPR symptoms and salivary pepsin levels.

Detailed Description

A cost-effective and care appropriate algorithm to streamline the diagnosis and management of patients with laryngopharyngeal reflux (LPR) has not been described. It is postulated that the incompetence of the upper esophageal sphincter (UES) to restrict passage of esophageal refluxate is fundamental to the development of LPR. The UES Assist Device (UESAD) is a novel device that applies relatively modest external cricoid pressure, which results in a 20 to 30 mmHg intraluminal UES pressure increase. Pepsin, a proteolytic enzyme produced in the stomach, has been detected in the laryngeal epithelium of patients with reflux associated laryngeal symptoms and implicated in the pathogenesis of laryngopharyngeal reflux. A study examining salivary pepsin levels for patients pre- and post-fundoplication for LPR found that all patients with positive preoperative pepsin levels and postoperative elimination had symptom improvement, suggesting that changes in pepsin level may be reflective of surgical responsiveness. This study seeks to explore the therapeutic role of the UESAD in patients with LPR symptoms, and measure its effectiveness by objective criteria (salivary pepsin) and symptomatic improvement. In this study, 25 patients seen in GI clinic with laryngeal complaints will complete validated symptom questionnaires - the RSI, GerdQ and N-GSSIQ scores. Those with an RSI \> 13 and GerdQ \> 8 will be included. They will submit 3 baseline sputum samples for pepsin analysis, taken upon awaking. They will then be advised to use the UESAD nightly for 2 weeks. 3 follow-up sputum samples for pepsin analysis will be taken and symptom scores reevaluated after the 2 week period.

Study Timeline

• Study Start: 2015-09-01
• Study First Submitted: 2015-09-16
• Study First Submitted QC: 2015-09-16
• Study First Posted: 2015-09-17
• Primary Completion: 2017-08-31
• Study Completion: 2018-08-31
• Results First Submitted: 2019-06-11
• Status Verified: 2019-07
• Results First Submitted QC: 2020-02-24
• Last Update Submitted: 2020-02-24
• Results First Posted: 2020-02-26
• Last Update Posted: 2020-02-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Male or female persons age 18-90
2. Patients with LPR symptoms (RSI >13)

Read More

Exclusion Criteria

1. Pregnant patients per history on initial evaluation.
2. Adults unable to consent in English
3. Patients who are currently imprisoned
4. Patients started on PPI therapy within 4 weeks of study
5. Patients with implants or implant parts that reside in the area where the REZA BAND is applied.
6. Patients with an implanted pacemaker, implanted cardioverter defibrillator (ICD), vagus nerve stimulator, or other such similar devices implanted in the neck.
7. Patients diagnosed with glaucoma.
8. Patients who had a malignancy of the neck, including neck surgery.
9. Patients that may have an altered mental status including due to the use of sedative drugs or narcotics.
10. Patients with carotid artery disease, thyroid disease, a history of cerebrovascular disease, or any disorder of connective tissues (e.g., Marfan's Syndrome or Ehlers-Danlos Syndrome).
11. Patients who use nocturnal NIV machines such as CPAP or BiPAP.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
UESAD	UESAD	Upper Esophageal Sphincter Assist Device

Primary Outcome Measures

Name	Time	Method
Salivary Pepsin Concentration	2 weeks	Average salivary pepsin concentration

Secondary Outcome Measures

Name	Time	Method
NGSSIQ Score	2 weeks	NGSSI questionnaire score
RSI Score	2 weeks	Respiratory symptom index (RSI) score. Values between 0 and 45. Higher value is associated with increased symptom severity.
GerdQ Score	2 weeks	GERDQ score. Scale of 0-12, higher score indicates increased symptom severity.